clinical trial · NCT07684235
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
ObesityOverweightMaridebart cafraglutidePlacebo
brief summary
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).
started
Jul 23, 2026
primary completion
Dec 26, 2027
completion
Mar 19, 2028
last updated
Aug 4, 2026
official title
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol